Lara Maloney
Overview
Explore the profile of Lara Maloney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
2557
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Colomban O, Swisher E, Kristeleit R, McNeish I, Shapira-Frommer R, Goble S, et al.
EBioMedicine
. 2023 Feb;
89:104477.
PMID: 36801617
Background: PARP inhibitors (PARPi) have revolutionized the management of advanced ovarian carcinoma, and were investigated as forefront treatment in recurrent disease. The objective was to explore if mathematical modeling of...
2.
Kristeleit R, Drew Y, Oza A, Domchek S, Banerjee S, Glasspool R, et al.
Br J Cancer
. 2022 Dec;
128(2):255-265.
PMID: 36482193
Background: Study 10, a four-part Phase 1/2 study, evaluated oral rucaparib monotherapy in patients with advanced solid tumours. Here we report the final efficacy and safety results in heavily pretreated...
3.
OMalley D, Oza A, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al.
Gynecol Oncol
. 2022 Oct;
167(3):404-413.
PMID: 36273926
Objective: ARIEL3 (NCT01968213) is a placebo-controlled randomized trial of the poly(ADP-ribose) polymerase inhibitor rucaparib as maintenance treatment in patients with recurrent high-grade ovarian carcinoma who responded to their latest line...
4.
Liao M, Beltman J, Giordano H, Harding T, Maloney L, Simmons A, et al.
Clin Pharmacokinet
. 2022 Sep;
61(11):1477-1493.
PMID: 36107395
Rucaparib is an oral small-molecule poly(ADP-ribose) polymerase inhibitor indicated for patients with recurrent ovarian cancer in the maintenance and treatment settings and for patients with metastatic castration-resistant prostate cancer associated...
5.
Green M, Ma S, Goble S, Giordano H, Maloney L, Simmons A, et al.
Cancer Chemother Pharmacol
. 2022 Apr;
89(5):671-682.
PMID: 35397664
Purpose: To develop a population pharmacokinetics (PPK) model for rucaparib, an oral poly(ADP-ribose) polymerase inhibitor. Methods: The PPK analysis used PK data from patients in Study 1014 (NCT01009190, n = ...
6.
Kwan T, Oza A, Tinker A, Ray-Coquard I, Oaknin A, Aghajanian C, et al.
JAMA Oncol
. 2021 Oct;
7(12):1772-1781.
PMID: 34647981
Importance: A total of 1% to 3% of patients treated with a poly(adenosine diphosphate-ribose) polymerase inhibitor for high-grade ovarian cancer (HGOC) develop therapy-related myeloid neoplasms (t-MNs), which are rare but...
7.
Swisher E, Kristeleit R, Oza A, Tinker A, Ray-Coquard I, Oaknin A, et al.
Gynecol Oncol
. 2021 Oct;
163(3):490-497.
PMID: 34602290
Objective: To describe molecular and clinical characteristics of patients with high-grade recurrent ovarian carcinoma (HGOC) who had long-term responses to the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib. Methods: This post hoc...
8.
Monk B, Coleman R, Fujiwara K, Wilson M, Oza A, Oaknin A, et al.
Int J Gynecol Cancer
. 2021 Oct;
31(12):1589-1594.
PMID: 34593565
Background: The optimal treatment strategy for women with newly diagnosed ovarian cancer has yet to be determined. Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated substantial improvement in progression-free survival as monotherapy...
9.
Oaknin A, Oza A, Lorusso D, Aghajanian C, Dean A, Colombo N, et al.
Cancer Med
. 2021 Sep;
10(20):7162-7173.
PMID: 34549539
Background: The efficacy and safety of rucaparib maintenance treatment in ARIEL3 were evaluated in subgroups based on best response to most recent platinum-based chemotherapy and baseline disease. Methods: Patients were...
10.
Swisher E, Kwan T, Oza A, Tinker A, Ray-Coquard I, Oaknin A, et al.
Nat Commun
. 2021 May;
12(1):2487.
PMID: 33941784
ARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc exploratory biomarker analysis of pre- and...